Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. Its marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) in... (Source: SEC reports)
Competitor - 1/8
Which company is more competitive with Regeneron Pharmaceuticals?
TARRYTOWN, N.Y., Feb. 12, 2018 /PRNewswire/ --Â Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced the appointment of Marion McCourt as the Senior Vice President and Head of Commercial. Ms. [...]
TARRYTOWN, N.Y., Oct. 11, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)Â today announced that it will report its third quarter 2017 financial and operating results on Wednesday, November [...]
TARRYTOWN, N.Y., Oct. 2, 2017 /PRNewswire/ --Â Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced two new collaborations with the Biomedical Advanced Research and Development Authority (BARDA), part of the [...]